Medulloblastoma: Molecular understanding, treatment evolution, and new developments

doi:10.1016/j.pharmthera.2020.107516

	Medulloblastoma: Molecular understanding, treatment evolution, and new developments
	Liu, Xiaohua 1,2,4; Ding, Chunyong 2,4; Tan, Wenfu 3; Zhang, Ao 1,2,4
刊名	PHARMACOLOGY & THERAPEUTICS
	2020-06-01
卷号	210 页码:13
关键词	Medulloblastoma Pediatric brain tumor Oncogenic driver gene Hedgehog pathway inhibitor Smoothened receptor antagonist
ISSN号	0163-7258
DOI	10.1016/j.pharmthera.2020.107516
通讯作者	Tan, Wenfu(wftan@fudan.edu.cn) ; Zhang, Ao(aozhang@simm.ac.cn)
英文摘要	Medulloblastoma (MB) is the most common childhood malignant brain tumor, accounting for approximately 20% of all pediatric central nervous systemtumors. Current standard treatments involving surgical interventions followed by craniospinal irradiation and adjuvant chemotherapy have severe motor and cognitive defects. Therefore, individualized treatment regimens with reduced toxicity designed according to the presence of specific oncogenic `driver' genes are urgently demanded. To this end, recent genetic and epigenetic findings have advanced the classification of MB into the international consensus of four distinct MB molecular subgroups (WNT, SHH, Group 3, and Group 4) based on their respective molecular and histopathological characteristics. More recent studies have indicated that up to seven molecular subgroups exist in childhood MB. Moreover, studies on the inter- and intra-tumoral features of the four subgroups revealed that each subgroup contains variant subtypes. These results have greatly helped risk stratification ofMB patients at diagnosis and significantly improved clinical treatment options. Herein, we highlight the recent advances and challenges associated with MB classification, and the development of therapeutic treatments targeting novel subgroup-specific molecular and epigenetic factors, especially those in the SHH-driven MB tumors. (C) 2020 Elsevier Inc. All rights reserved.
资助项目	National Natural Science Foundation of China[81773565] ; Chinese Academy of Sciences[160621] ; Strategic Leading Project A on Precision Medicine of the Chinese Academy of Sciences[XDA12020374] ; Strategic Leading Project A on Precision Medicine of the Chinese Academy of Sciences[XDA12020226] ; Strategic Leading Project A on Precision Medicine of the Chinese Academy of Sciences[XDA1250400] ; Shanghai Jiao Tong University
WOS关键词	INVESTIGATIONAL DRUG TAK-441 ; HISTONE LYSINE METHYLATION ; ACUTE MYELOID-LEUKEMIA ; HEDGEHOG PATHWAY ; CHILDHOOD MEDULLOBLASTOMA ; OUTCOME PREDICTION ; STRUCTURAL BASIS ; INHIBITOR ; DISCOVERY ; TARGET
WOS研究方向	Pharmacology & Pharmacy
语种	英语
出版者	PERGAMON-ELSEVIER SCIENCE LTD
WOS记录号	WOS:000533607500004
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/280340]
专题	中国科学院上海药物研究所
通讯作者	Tan, Wenfu; Zhang, Ao
作者单位	1.Univ Chinese Acad Sci, Beijing 100049, Peoples R China 2.Chinese Acad Sci, Shanghai Inst Mat Med SIMM, CAS Key Lab Receptor Res, Shanghai 201203, Peoples R China 3.Fudan Univ, Sch Pharm, Dept Pharmacol, Shanghai 201203, Peoples R China 4.Shanghai Jiao Tong Univ, Sch Pharm, Res Lab Med Chem Biol, Frontiers Drug Discovery RLMCBFDD, Shanghai 200240, Peoples R China
推荐引用方式 GB/T 7714	Liu, Xiaohua,Ding, Chunyong,Tan, Wenfu,et al. Medulloblastoma: Molecular understanding, treatment evolution, and new developments[J]. PHARMACOLOGY & THERAPEUTICS,2020,210:13.
APA	Liu, Xiaohua,Ding, Chunyong,Tan, Wenfu,&Zhang, Ao.(2020).Medulloblastoma: Molecular understanding, treatment evolution, and new developments.PHARMACOLOGY & THERAPEUTICS,210,13.
MLA	Liu, Xiaohua,et al."Medulloblastoma: Molecular understanding, treatment evolution, and new developments".PHARMACOLOGY & THERAPEUTICS 210(2020):13.